|1.||Gandhi, Varsha: 9 articles (03/2010 - 06/2002)|
|2.||Robson, Simon C: 8 articles (07/2012 - 04/2002)|
|3.||Plunkett, William: 6 articles (03/2008 - 10/2002)|
|4.||Renshaw, Perry F: 5 articles (11/2015 - 01/2007)|
|5.||Nelson, David S: 4 articles (03/2015 - 12/2007)|
|6.||Glickson, Jerry D: 4 articles (03/2015 - 12/2007)|
|7.||Leal, Daniela Bitencourt Rosa: 4 articles (07/2013 - 01/2012)|
|8.||Schetinger, Maria Rosa Chitolina: 4 articles (07/2013 - 01/2012)|
|9.||Petrone, M E: 4 articles (01/2000 - 01/2000)|
|10.||Volpe, A R: 4 articles (01/2000 - 01/2000)|
06/15/1991 - "In this study, we directly measured the effect of tumor bed irradiation on blood flow, growth rate, rate of nucleoside triphosphate (NTP) turnover, and metabolic state using 31P and 2H nuclear magnetic resonance, and an intradermal assay for angiogenesis. "
10/06/2015 - "As the phosphoinositol-3-kinase antagonist in the PI3K pathway, the PTEN tumor suppressor exerts phosphatase activity on diacylphosphatidylinositol triphosphate in the plasma membrane. "
03/01/2015 - "Following treatment with LND, each of these tumors exhibits a rapid decrease in intracellular pH, a small decrease in extracellular pH, a concomitant monotonic decrease in nucleoside triphosphate and an increase in inorganic phosphate over a 2-3 h period. "
12/01/2010 - "In contrast, 25 μM PIC inhibited deoxynucleotide triphosphate synthesis, activated Chk2 and p38-MAPK and this was accompanied by an attenuation of cancer cell growth. "
09/01/2010 - "Finally, inhibition of CD39 activity by polyoxometalate-1, a pharmacologic inhibitor of nucleoside triphosphate diphosphohydrolase activity, significantly inhibited tumor growth (P < .001). "
12/01/2007 - "Coating the kibbles with sodium tripolyphosphate, an anti-calculus agent, further induced a 55.0% calculus reduction. "
01/01/2003 - "A six-week study to evaluate the anti-calculus efficacy of a chewing gum containing pyrophosphate and tripolyphosphate."
01/01/2003 - "A twelve-week clinical study was conducted to evaluate the effect of a chewing gum containing pyrophosphate (1%) and tripolyphosphate (1%) on controlling supragingival calculus deposits. "
01/01/2003 - "A six-week, double-blind, cross-over clinical study was conducted to compare the effect of a new chewing gum containing pyrophosphate (1%) and tripolyphosphate (1%), versus a control chewing gum on supragingival calculus deposits. "
01/01/2003 - "The results indicated that a chewing gum containing tripolyphosphate and pyrophosphate reduced calculus formation by 37.6% compared to a no gum treatment."
|3.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
06/15/1987 - "The intracellular half-life for retention of the active triphosphate metabolite 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (araCTP) of 1-beta-D-arabinofuranosylcytosine was measured in vitro in blast cells from patients with acute myeloblastic leukemia, acute lymphoblastic leukemia, and T-cell lymphoblastic lymphoma. "
08/01/1987 - "The place of cytosine arabinoside (araC) in the treatment of T-cell acute lymphoblastic leukemia was studied by measuring nucleoside transport sites and the conversion of araC to its triphosphate (araCTP) in lymphoblasts from the peripheral blood of two patients, who were then treated with araC. "
11/01/1974 - "Terminal deoxyribonucleotidyl transferase (EC 18.104.22.168; nucleoside triphosphate:DNA nucleotidylexotransferase) is usually found only in thymus, but has been reported in leukemic cells from children with acute lymphoblastic leukemia. "
06/23/1993 - "Arabinosylguanine (araG) is a nucleoside analogue that is rapidly converted by cells of the T lymphoid lineage to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and selective in vitro toxicity to T lymphoblastoid cell lines as well as to freshly isolated leukemia cells from patients with T cell acute lymphoblastic leukemia (ALL). "
10/01/1991 - "Arabinosylguanine (araG) is a nucleoside analog that is rapidly converted by cells of the T lymphoid lineage to its corresponding arabinosylguanine nucleotide triphosphate, resulting in inhibition of DNA synthesis and selective in vitro toxicity to T lymphoblastoid cell lines as well as to freshly isolated leukemia cells from patients with T cell acute lymphoblastic leukemia. "
01/15/2015 - "EGCG, EA, and RA dose-dependently inhibited the growth of human HL-60 promyelocytic leukemia cells, exerted strong free radical scavenging potential, and significantly imbalanced nuclear deoxyribonucleoside triphosphate (dNTP) concentrations without distinctly affecting the protein levels of RR subunits (R1, R2, p53R2). "
12/01/1990 - "Metabolism and toxicity of electroporated 1-beta-D-arabinofuranosylcytosine triphosphate in a human leukemia cell line."
03/01/2008 - "To test whether nelarabine is an effective agent for indolent leukemias and to evaluate whether there is a relationship between cellular pharmacokinetics of the analog triphosphate and clinical responses. "
10/01/2004 - "In phase II studies, the relationship between the pharmacokinetics of clofarabine triphosphate accumulation and clinical response at the MTD was explored, revealing an accumulation advantage of the cytotoxic triphosphate in leukemia cells of responders. "
12/15/2003 - "The purpose of our study was to investigate the pharmacology of clofarabine and its triphosphate and the pharmacodynamic actions in circulating blasts obtained from acute leukemia patients who entered a Phase I clinical trial of clofarabine. "
08/15/1957 - "Tetracalcium hydrogen triphosphate trihydrate, a constituent of dental calculus."
01/01/2001 - "Caries inhibition in rats by a sodium fluoride, tripolyphosphate toothpaste with whitening and anti-tartar properties."
01/01/2001 - "The anti-caries properties of a silica-based, sodium fluoride (NaF) toothpaste containing sodium tripolyphosphate (NaTPP) with tooth whitening and anti-tartar properties (Aquafresh Whitening), in specific pathogen-free Osborne-Mendel rats, were assessed in this study. "
01/01/2000 - "The objective of this double-blind clinical study, conducted using the Volpe-Manhold evaluation method for dental calculus, was to compare the effect on supragingival calculus formation of a dentifrice containing tetrasodium pyrophosphate, sodium tripolyphosphate, and a copolymer in a 0.243% sodium fluoride/silica base (Test Dentifrice), to that of a commercially available calculus-inhibiting dentifrice containing tetrasodium pyrophosphate and a copolymer in a 0.243% sodium fluoride/silica base (Positive Control Dentifrice). "
01/01/2000 - "The objective of this double-blind clinical study, conducted in harmony with the Volpe-Manhold design for studies of dental calculus, was to compare the effect on supragingival calculus formation of a dentifrice containing pyrophosphate, tripolyphosphate and a copolymer in a 0.243% sodium fluoride/silica base (Test Dentifrice), to that of a commercially available calculus-inhibiting dentifrice containing tetrapotassium pyrophosphate, disodium pyrophosphate and tetrasodium pyrophosphate in a 0.243% sodium fluoride/silica base (Positive Control Dentifrice). "
|2.||Sodium Fluoride (Ossin)
|3.||Silicon Dioxide (Sand)
|5.||sodium pyrophosphate (disodium pyrophosphate)
|6.||methoxyethylene-maleic anhydride copolymer
|3.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)
|5.||Highly Active Antiretroviral Therapy (HAART)